Q: Which GS Paper does Science & Technology fall under for UPSC?

Science & Technology topics are covered under GS3 in the UPSC Prelims and Mains syllabus. Current affairs on Science & Technology are regularly tested in UPSC examinations and require understanding of both policy dimensions and current developments.

Q: How is this current affair relevant for UPSC Mains answer writing?

For UPSC Mains, "Health Ministry to amend 2019 rules for new drugs, clinical trials" can be linked to GS3 questions on Science & Technology. Focus on the causes, government response, challenges, and way forward. Use data points and connect it with relevant schemes and constitutional provisions for a high-scoring Mains answer.

The Union Health Ministry’s amendment to the 2019 New Drugs and Clinical Trials Rules aims to halve test‑licence applications and cut processing time from 90 to 45 days, thereby accelerating bioavailability/bioequivalence studies. This regulatory reform is crucial for UPSC aspirants as it links health governance, pharmaceutical innovation and ease‑of‑doing‑business, topics frequently tested in GS‑2 and GS‑3.

Aimed at promoting ease of doing business in the pharmaceutical and clinical research sectors, the Union Health Ministry is set to amend the New Drugs and Clinical Trials Rules, 2019. The proposed amendments were published in The Gazette of India on August 28, seeking public comments. The amendments aim to simplify the requirements and procedures for obtaining test licences, and for submitting applications related to studies on bioavailability/bioequivalence. The key highlights of the proposed amendments, according to the release issued by the Health Ministry on Wednesday (September 3, 2025), includes easing up application processes for test licences, and for studies on bioavailability/bioequivalence. Under the proposed amendment, the present system for test licenses has been converted to a notification and intimation system, the statement said. “Through this, the applicants need not wait for test licenses (except a small category of high-risk category drugs) but will need to just intimate the Central Licensing Authority. Additionally, the overall statutory processing time for test licence applications will be reduced from 90 days to 45 days,’’ the Ministry said. Thus, under the amendment, the existing licence requirement will be dispensed with for certain categories of bioavailability/bioequivalence studies, which may instead be initiated upon the submission of an intimation or notification to the Central Licensing Authority. These regulatory reforms are expected to benefit stakeholders by significantly reducing the timelines for processing applications. They will also reduce the number of applications for test licenses being submitted by approximately 50%. “This will facilitate quicker initiation of bioavailability/bioequivalence studies, testing and examination of drugs for research, and reduce delays in the drug development and approval processes,’’ the Ministry said. The amendments would enable the Central Drugs Standard Control Organisation to optimise the deployment of its human resources, thereby enhancing the efficiency and effectiveness of regulatory oversight, the Health Ministry said.

Overview

Full Article

Analysis